Novartis ESMO Event Presentation
PSMAfore was specifically designed to address key unmet needs
in mCRPC
Dosing
regimen
Choice of
comparator
Crossover
design
Insights
Low kidney uptake enables 6 cycles of
Pluvicto at 7.4 GBq, already proven in
the sicker post-taxane setting
Many patients unwilling or ineligible to
take taxane-based chemotherapy, due
to debilitating side effects
Strong results in VISION increased
risk of dropout in PSMAfore
control arm
PSMAfore trial design
Maintain dosing regimen for pre-taxane population
to optimize radiation delivery
Compare to change in ARPI, to potentially allow
patients to reduce, eliminate or delay chemo
Study allowed patients on control arm to receive
Pluvicto after centrally confirmed radiographic
progression
Pre-specified primary OS analysis adjusted for
crossover because of this confounding factor
12 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION
NOVARTIS | Reimagining MedicineView entire presentation